Brokerages Set Integra LifeSciences Holdings Co. (NASDAQ:IART) Target Price at $27.25

Integra LifeSciences Holdings Co. (NASDAQ:IART) has been assigned an average rating of “Reduce” from the eight ratings firms that are currently covering the firm, Marketbeat Ratings reports. Three investment analysts have rated the stock with a sell recommendation, four have given a hold recommendation and one has assigned a buy recommendation to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $24.00.

A number of brokerages have recently issued reports on IART. BTIG Research raised Integra LifeSciences from a “sell” rating to a “neutral” rating in a research report on Monday, October 7th. Bank of America reduced their target price on Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating on the stock in a research report on Monday, October 7th. JMP Securities dropped their price target on Integra LifeSciences from $40.00 to $35.00 and set a “market outperform” rating on the stock in a research note on Tuesday, July 30th. Citigroup upped their price objective on shares of Integra LifeSciences from $16.00 to $22.00 and gave the company a “sell” rating in a report on Tuesday, November 5th. Finally, Truist Financial dropped their target price on shares of Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating on the stock in a research report on Monday, October 14th.

Integra LifeSciences Trading Down 1.7 %

Shares of NASDAQ IART opened at $22.49 on Tuesday. Integra LifeSciences has a 1-year low of $16.81 and a 1-year high of $45.42. The business has a fifty day moving average price of $19.64 and a 200 day moving average price of $24.09. The stock has a market capitalization of $1.74 billion, a P/E ratio of -249.86, a price-to-earnings-growth ratio of 0.78 and a beta of 1.08. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.20 and a quick ratio of 0.73.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings results on Monday, November 4th. The life sciences company reported $0.41 EPS for the quarter, beating the consensus estimate of $0.39 by $0.02. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The business had revenue of $380.80 million during the quarter, compared to analyst estimates of $375.81 million. During the same period in the prior year, the firm posted $0.76 earnings per share. The company’s quarterly revenue was down .4% on a year-over-year basis. Equities research analysts expect that Integra LifeSciences will post 2.45 EPS for the current fiscal year.

Institutional Trading of Integra LifeSciences

Institutional investors and hedge funds have recently bought and sold shares of the business. Blue Trust Inc. raised its holdings in shares of Integra LifeSciences by 100.5% during the second quarter. Blue Trust Inc. now owns 886 shares of the life sciences company’s stock worth $26,000 after purchasing an additional 444 shares during the last quarter. CWM LLC raised its position in Integra LifeSciences by 50.8% during the second quarter. CWM LLC now owns 1,262 shares of the life sciences company’s stock valued at $37,000 after acquiring an additional 425 shares in the last quarter. KBC Group NV lifted its holdings in Integra LifeSciences by 65.2% in the third quarter. KBC Group NV now owns 2,839 shares of the life sciences company’s stock valued at $52,000 after acquiring an additional 1,120 shares during the period. Northwest Investment Counselors LLC purchased a new stake in Integra LifeSciences in the 3rd quarter worth approximately $73,000. Finally, Canada Pension Plan Investment Board acquired a new stake in shares of Integra LifeSciences during the 2nd quarter worth approximately $114,000. 84.78% of the stock is currently owned by institutional investors and hedge funds.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.